Medicaid Drug Rebate Program (MDRP) Summit 2025
IntegriChain was proud to sponsor the 2025 Medicaid Drug Rebate Program (MDRP) conference, contributing thought leadership on key topics such as the Inflation Reduction Act (IRA) rebates, IRA drug price negotiations, and best practices around this topic. Our sessions delved into the latest IRA Medicare Part D changes, offering insights and best practices for navigating this evolving landscape and how pharmaceutical manufacturers can prepare for new rebates.
Lynetta Moore
Director of State Price Transparency Reporting
Kirsten Midtbo
Senior Manager
MDRP 2025 | Session #1: Navigating the Shifting Landscape of State Price Transparency Reporting (STPR)
Date/Time: Monday, September 15, 2025 | 8:40AM – 9:25 AM
Description: In this session, Lynetta Moore, Director of State Price Transparency Reporting, and Kirsten Midtbo, Senior Manager, will cover topics including:
- Gain insight into evolving reporting obligations with a clear overview of timelines and requirements.
- Trends to watch in state requirements and practical strategies for proactive compliance in a fragmented landscape.
- Exploring approaches to maintain consistent, accurate reporting while responsibly addressing proprietary information consideration.
Jeff Baab
Partner, Advisory Services
MDRP 2025 | Session #2: IRA Implementation at the Crossroads: Strategic Decision Framework for 2026 and Beyond
Date/Time: Wednesday, September 17, 2025 | 8:10 AM – 8:50 AM
Description: In this session, Jeff Baab, Partner, Advisory Services and Kristin Hicks, Partner at Arnold and Porter, will cover topics including:
- Examine strategic inflection points as the IRA transitions from initial implementation to mature program operations, including essential recalibrations for commercial planning, forecasting, and portfolio optimization.
- Analyze emerging patterns in market response across different stakeholder groups, illuminating how successful organizations are adapting their decision frameworks beyond basic compliance.
- Explore the evolution of data-driven approaches for navigating negotiation preparation, financial modeling, and commercial contracting in response to early program experiences.
- Develop forward-looking strategies that balance short-term tactical needs with long-term portfolio considerations as the program expands to include Part B drugs and additional therapeutic categories.
Clay Willis
Partner, Advisory
MDRP 2025 | Session #3: 340B Rebate Pilot Program – What this Means for Manufacturers and Key Planning Considerations
Date/Time: Wednesday, September 17, 2025 | 10:50 AM – 11:30 AM
Description: In this session, Clay Willis, Partner, Advisory Services, will explore the concept of a 340B Rebate Model. This is somewhat new to the industry as a whole so in this session we will discuss how the industry got here, an overview of the 340B Rebate Model Pilot Program and its requirements, and manufacturer considerations for both those that can participate and those who (for now) cannot participate in the pilot program.
Join Integrichain at the 2025 MDRP Summit for leading insights into compliance, rebate strategy, and government pricing – register today to learn more.